Company: PSTV
Filing Date: 2025-07-11
Form Type: PRE 14A
Source: 0001140361-25-025650
Chunk: 81

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-07-11
Form: PRE 14A
Chunk 81
---
 engage consultants from time to time who are eligible to receive awards under the Fifth Amended Plan. Administration The Fifth Amended Plan is administered by the Compensation Committee of our Board. Subject to the limitations set forth in the Fifth Amended Plan, the Compensation Committee has the authority to determine, among other things, to whom awards will be granted, the number of shares subject to awards, the term during

52

TABLE OF CONTENTS which an option, stock unit or stock appreciation right may be exercised and the rate at which the awards may vest or be earned, including any performance criteria to which they may be subject. The Compensation Committee also has the authority to determine the consideration and methodology of payment for awards. The Compensation Committee, our Board and any of their designees do not have the authority to: (i) amend the terms of an outstanding option or stock appreciation right to reduce its exercise price, or (ii) cancel outstanding options or stock appreciation rights with an exercise price above the then-current fair market value per share in exchange for another option, stock appreciation right with a lower exercise price or for other award or for cash, unless the stockholders of the Company have previously approved such an action or if the action relates to a capitalization adjustment under the terms of the Fifth Amended Plan. Shares Available for Awards Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be issued under the Fifth Amended Plan will not exceed 21,303,334 shares, which is the sum of (i) 36,667 shares approved at the Company’s 2020 annual meeting of stockholders, plus(ii) 66,667 shares approved at the Company’s 2021 annual meeting of stockholders, plus(iii) 133,333 shares approved at the Company’s 2022 annual meeting of stockholders, plus(iv) 66,667 shares approved at the Company’s 2023 annual meeting of stockholders, plus(v) 1,000,000 Shares approved at the Company’s 2024 annual meeting of stockholders, plus(vi) 20,000,000 Shares approved at the Company’s 2025 annual meeting of stockholders, plus(vii) the number of unallocated shares remaining available for grant under the Plus Therapeutics, Inc. 2014 Equity Incentive Plan, as amended (the “2014 Plan”) as of the effective date of the Plan, plus(viii) the Predecessor Plan’s Returning Shares (as defined below